Alpine Immune Sciences Past Earnings Performance
Past criteria checks 0/6
Alpine Immune Scienceshan disminuido a un ritmo medio anual de -11.2%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a una tasa media anual de 53.1%.
Key information
-7.9%
Earnings growth rate
15.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 53.1% |
Return on equity | -9.8% |
Net Margin | -54.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts
Mar 21Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug
Mar 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up
Feb 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up
Dec 19We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
May 11Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Alpine Immune Sciences drops 13% after hours on $100M stock offering
Sep 20Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Alpine: Rest Before Rallying Again
Apr 25Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right
Jun 03Alpine Immune Sciences files for $150M mixed shelf offering
May 26Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 29How Many Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Did Insiders Buy, In The Last Year?
Mar 03The Alpine Immune Sciences (NASDAQ:ALPN) Share Price Is Up 316% And Shareholders Are Delighted
Feb 05What Kind Of Shareholders Own Alpine Immune Sciences, Inc. (NASDAQ:ALPN)?
Jan 10Alpine: Is This A Young Oak Tree?
Jan 05Does Alpine Immune Sciences (NASDAQ:ALPN) Have A Healthy Balance Sheet?
Dec 15Revenue & Expenses BreakdownBeta
How Alpine Immune Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 59 | -32 | 22 | 0 |
30 Sep 23 | 31 | -57 | 20 | 0 |
30 Jun 23 | 29 | -59 | 19 | 0 |
31 Mar 23 | 26 | -64 | 19 | 0 |
31 Dec 22 | 30 | -58 | 18 | 0 |
30 Sep 22 | 32 | -54 | 18 | 0 |
30 Jun 22 | 32 | -54 | 17 | 0 |
31 Mar 22 | 34 | -47 | 16 | 0 |
31 Dec 21 | 23 | -50 | 15 | 0 |
30 Sep 21 | 25 | -42 | 13 | 0 |
30 Jun 21 | 18 | -34 | 12 | 0 |
31 Mar 21 | 11 | -33 | 12 | 0 |
31 Dec 20 | 9 | -28 | 11 | 0 |
30 Sep 20 | 5 | -28 | 10 | 0 |
30 Jun 20 | 3 | -33 | 10 | 0 |
31 Mar 20 | 3 | -35 | 9 | 0 |
31 Dec 19 | 2 | -42 | 9 | 0 |
30 Sep 19 | 1 | -47 | 10 | 0 |
30 Jun 19 | 1 | -48 | 9 | 0 |
31 Mar 19 | 0 | -44 | 9 | 0 |
31 Dec 18 | 1 | -36 | 8 | 0 |
30 Sep 18 | 1 | -30 | 7 | 0 |
30 Jun 18 | 1 | -15 | 7 | 0 |
31 Mar 18 | 1 | -11 | 6 | 0 |
31 Dec 17 | 2 | -8 | 5 | 0 |
30 Sep 17 | 2 | -5 | 4 | 0 |
30 Jun 17 | 3 | -7 | 2 | 0 |
31 Mar 17 | 3 | -3 | 2 | 0 |
31 Dec 16 | 3 | -1 | 1 | 0 |
31 Dec 15 | 0 | 0 | 0 | 0 |
Beneficios de calidad: ALPN actualmente no es rentable.
Creciente margen de beneficios: ALPN actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: ALPN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 11.2% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ALPN en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: ALPN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Return on Equity
Alto ROE: ALPN tiene un Rendimiento de los fondos propios negativo (-35.27%), ya que actualmente no es rentable.